Anavex Life Sciences Corp (AVXL)

[kevli33]

From 2018 Research Report at Hammond Care (page 38)

Dementia
ANAVEX trial- A phase 2b/3, double-blind, randomised, placebo- controlled 48-week safety and efficacy trial of ANAVEX2-73 for the treatment of Alzheimer’s disease | New in 2018
Associate Professor Macfarlane’s study team has been involved in testing the ANAVEX2-73 molecule since 2014 and were heavily involved in writing and editing the previous phase 2a, and current phase 2b/3, protocols. ANAVEX2-73 is a novel compound that is thought to act on the sigma 1 intracellular receptor.
Its mode of action is unique in that most (if not all) other molecules developed thus far to treat Alzheimer’s Disease target the removal of a single type of toxic protein (either beta amyloid or Tau). In contrast, ANAVEX2-73 is thought to remove all forms of misfolded proteins from brain cells.
While involved in the phase 2a study, Associate Professor Macfarlane and his team saw positive (and at times drastic) increases in cognition and functioning in study participants, and are pleased to be involved in the phase 2b/3 study. The study will be recruiting throughout 2019 and most likely 2020 and into early 2021.
Some key achievements of the HammondCare site in relation to this study include:
1. Associate Professor Stephen Macfarlane has been appointed as the global study lead for this study
2. The Malvern site was the first site in the world to be initiated
3. Ours is the global No.1 recruiting site (most sites average 7-10 patients per study, whilst Malvern already has 31 patients on study and aims to recruit 40-50 patients)
4. This trial is currently being conducted at over 15 sites globally and will run for another 24 months.

https://www.hammond.com.au/documents/research-reports/404-2018-hammondcare-researchreport/file

Dementia is the greatest cause of disability in older Australians. Despite this, most research on reablement excludes people living with dementia. Learn about HammondCare's reablement research in the latest Research Report: https://t.co/nUnezeYU6p #agedcare #dementia pic.twitter.com/6Z1tvNUgfR

— HammondCare (@HammondCare) July 29, 2019